Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:40 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 531739 | NSE: GENNEX

Gennex Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹8.71Fairly Valued by 1.87%vs CMP ₹8.55

P/E (11.9) × ROE (10.2%) × BV (₹8.79) × DY (2.00%)

₹9.64Undervalued by 12.75%vs CMP ₹8.55
MoS: +11.3% (Thin)Confidence: 43/100 (Low)Models: 4 Under, 1 Fair, 4 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹11.1723%Under (+30.6%)
Graham NumberEarnings₹12.0217%Under (+40.6%)
Earnings PowerEarnings₹0.6611%Over (-92.3%)
DCFCash Flow₹16.5511%Under (+93.6%)
Net Asset ValueAssets₹8.767%Fair (+2.5%)
EV/EBITDAEnterprise₹2.639%Over (-69.2%)
Earnings YieldEarnings₹7.307%Over (-14.6%)
ROCE CapitalReturns₹15.979%Under (+86.8%)
Revenue MultipleRevenue₹5.676%Over (-33.7%)
Consensus (9 models)₹9.64100%Undervalued
Key Drivers: EPS CAGR 28.3% lifts DCF — verify sustainability. | Wide model spread (₹1–₹17) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 28.3%

*Investments are subject to market risks

Investment Snapshot

63
Gennex Laboratories Ltd scores 63/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health76/100 · Strong
ROCE 13.0% GoodROE 10.2% AverageD/E 0.18 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 23.6% Stable
Earnings Quality55/100 · Moderate
OPM expanding (8% → 16%) ImprovingWorking capital: 214 days Capital intensive
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +14% YoY GrowingProfit (4Q): 0% YoY Declining
Industry Rank75/100 · Strong
P/E 11.9 vs industry 53.8 Cheaper than peersROCE 13.0% vs industry 16.4% Average3Y sales CAGR: 31% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:40 am

Market Cap 208 Cr.
Current Price 8.55
Intrinsic Value₹9.64
High / Low 17.2/7.05
Stock P/E11.9
Book Value 8.79
Dividend Yield0.00 %
ROCE13.0 %
ROE10.2 %
Face Value 1.00
PEG Ratio0.42

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Gennex Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Gennex Laboratories Ltd 208 Cr. 8.55 17.2/7.0511.9 8.790.00 %13.0 %10.2 % 1.00
Ambalal Sarabhai Enterprises Ltd 203 Cr. 26.5 42.0/23.111.4 19.20.00 %9.12 %6.25 % 10.0
Everest Organics Ltd 215 Cr. 221 536/19736.7 74.70.00 %1.76 %2.23 % 10.0
BDH Industries Ltd 219 Cr. 381 524/24121.0 1231.18 %17.8 %14.2 % 10.0
Nectar Lifescience Ltd 190 Cr. 9.76 28.3/9.20 32.00.00 %5.36 %11.2 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Gennex Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 14.6320.8016.5218.1821.3935.5228.3233.3840.0140.3334.1839.3042.96
Expenses 12.8117.2811.4212.4116.5929.2624.1025.9232.8638.3129.1131.7434.39
Operating Profit 1.823.525.105.774.806.264.227.467.152.025.077.568.57
OPM % 12.44%16.92%30.87%31.74%22.44%17.62%14.90%22.35%17.87%5.01%14.83%19.24%19.95%
Other Income 0.000.000.000.000.000.002.470.000.003.682.280.00-0.30
Interest 0.190.630.730.780.830.730.730.220.841.200.981.031.11
Depreciation 0.180.370.651.030.450.230.451.110.500.540.500.470.52
Profit before tax 1.452.523.723.963.525.305.516.135.813.965.876.066.64
Tax % 24.83%19.05%23.39%22.47%21.31%15.28%15.43%12.23%12.91%22.22%14.48%9.08%9.79%
Net Profit 1.082.042.853.072.764.504.665.385.063.075.015.516.00
EPS in Rs 0.070.120.160.170.150.200.190.210.200.100.200.210.22

Last Updated: March 3, 2026, 9:36 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 27, 2026, 5:46 am

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 4244565660616687138157
Expenses 3742525253566170121134
Operating Profit 5243755171723
OPM % 11%5%7%6%11%9%7%20%12%15%
Other Income 01110145106
Interest 1111111344
Depreciation 1111111222
Profit before tax 3133556162123
Tax % 13%42%26%27%20%23%23%20%15%
Net Profit 3122445131820
EPS in Rs 0.140.040.120.100.210.210.280.580.800.73
Dividend Payout % 0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-66.67%100.00%0.00%100.00%0.00%25.00%160.00%38.46%
Change in YoY Net Profit Growth (%)0.00%166.67%-100.00%100.00%-100.00%25.00%135.00%-121.54%

Gennex Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:20%
3 Years:31%
TTM:43%
Compounded Profit Growth
10 Years:%
5 Years:56%
3 Years:61%
TTM:13%
Stock Price CAGR
10 Years:15%
5 Years:20%
3 Years:17%
1 Year:-38%
Return on Equity
10 Years:%
5 Years:9%
3 Years:9%
Last Year:9%

Last Updated: September 5, 2025, 3:36 pm

Balance Sheet

Last Updated: December 4, 2025, 2:56 am

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 13131313131318232324
Reserves 18192123273162148164189
Borrowings 4255710161088
Other Liabilities 14161316121451545955
Total Liabilities 495052575968132230256357
Fixed Assets 16161615141474566076
CWIP 0000000250
Investments 7777770000
Other Assets 26282935384859172191281
Total Assets 495052575968132230256357

Reserves and Borrowings Chart

Cash Flow

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + -032-2-11224-47-11
Cash from Investing Activity + -1-1-1-0-0-2-38191
Cash from Financing Activity + 1-21-02-221745
Net Cash Flow -002-208646-5
Free Cash Flow -121-2-210-16-31-20
CFO/OP 13%190%55%-52%1%242%505%-274%-45%

Free Cash Flow

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow1.000.00-1.00-2.000.00-5.004.0011.007.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 908768415567527537
Inventory Days 433157785072139184135
Days Payable 139161888659726311149
Cash Conversion Cycle -7-4338344667129148123
Working Capital Days 747556871088723255214
ROCE %6%11%8%14%12%11%14%12%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 23.38%23.38%23.61%23.61%18.41%18.41%18.41%18.41%18.41%19.82%23.62%23.62%
Public 76.62%76.62%76.39%76.39%81.58%81.57%81.59%81.58%81.58%80.17%76.38%76.39%
No. of Shareholders 55,60952,98150,98869,72383,99687,82090,23692,50692,32691,18390,32086,306

Shareholding Pattern Chart

No. of Shareholders

Gennex Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 0.800.660.420.330.32
Diluted EPS (Rs.) 0.780.660.420.330.32
Cash EPS (Rs.) 0.880.680.320.370.38
Book Value[Excl.RevalReserv]/Share (Rs.) 8.217.494.463.463.14
Book Value[Incl.RevalReserv]/Share (Rs.) 8.217.494.463.463.14
Revenue From Operations / Share (Rs.) 6.063.813.644.844.72
PBDIT / Share (Rs.) 1.190.960.470.530.55
PBIT / Share (Rs.) 1.110.860.420.470.48
PBT / Share (Rs.) 0.940.720.350.400.40
Net Profit / Share (Rs.) 0.790.570.270.310.31
NP After MI And SOA / Share (Rs.) 0.790.570.270.310.31
PBDIT Margin (%) 19.6825.2913.1711.0411.83
PBIT Margin (%) 18.2422.5611.779.7510.35
PBT Margin (%) 15.5119.019.718.328.48
Net Profit Margin (%) 13.1415.197.506.406.76
NP After MI And SOA Margin (%) 13.1415.197.506.406.76
Return on Networth / Equity (%) 9.707.736.128.9510.16
Return on Capital Employeed (%) 11.8910.317.5113.6215.49
Return On Assets (%) 7.075.723.715.766.85
Total Debt / Equity (X) 0.050.030.010.230.18
Asset Turnover Ratio (%) 0.560.470.650.961.03
Current Ratio (X) 4.074.011.651.951.98
Quick Ratio (X) 3.263.391.121.631.71
Inventory Turnover Ratio (X) 4.512.834.006.275.49
Interest Coverage Ratio (X) 7.527.136.397.709.49
Interest Coverage Ratio (Post Tax) (X) 6.065.284.635.476.93
Enterprise Value (Cr.) 236.62310.2093.2497.0755.76
EV / Net Operating Revenue (X) 1.723.581.421.590.93
EV / EBITDA (X) 8.7214.1410.7814.367.90
MarketCap / Net Operating Revenue (X) 1.994.141.541.560.82
Price / BV (X) 1.472.111.262.171.25
Price / Net Operating Revenue (X) 1.994.141.541.560.82
EarningsYield 0.060.030.040.040.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Gennex Laboratories Ltd. is a Public Limited Listed company incorporated on 29/03/1990 and has its registered office in the State of Telangana, India. Company's Corporate Identification Number(CIN) is L24230TG1990PLC011168 and registration number is 011168. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 94.58 Cr. and Equity Capital is Rs. 22.74 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsSy. No.133, Sangareddy Dist. Telangana 502325Contact not found
Management
NamePosition Held
Mr. Arihant BaidManaging Director
Dr. A R R PantuluNon Executive Director
Mr. Sandeep Kumar DagaNon Executive Director
Mr. A S Nageswar RaoIndependent Director
Mr. Dilip Raj SinghviIndependent Director
Ms. Shilpa BungIndependent Woman Director

FAQ

What is the intrinsic value of Gennex Laboratories Ltd and is it undervalued?

As of 12 April 2026, Gennex Laboratories Ltd's intrinsic value is ₹9.64, which is 12.75% higher than the current market price of ₹8.55, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (10.2 %), book value (₹8.79), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Gennex Laboratories Ltd?

Gennex Laboratories Ltd is trading at ₹8.55 as of 12 April 2026, with a FY2026-2027 high of ₹17.2 and low of ₹7.05. The stock is currently near its 52-week low. Market cap stands at ₹208 Cr..

How does Gennex Laboratories Ltd's P/E ratio compare to its industry?

Gennex Laboratories Ltd has a P/E ratio of 11.9, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Gennex Laboratories Ltd financially healthy?

Key indicators for Gennex Laboratories Ltd: ROCE of 13.0 % is moderate. Dividend yield is 0.00 %.

Is Gennex Laboratories Ltd profitable and how is the profit trend?

Gennex Laboratories Ltd reported a net profit of ₹18 Cr in Mar 2025 on revenue of ₹138 Cr. Compared to ₹4 Cr in Mar 2022, the net profit shows an improving trend.

Does Gennex Laboratories Ltd pay dividends?

Gennex Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹8.55. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gennex Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports